PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Mar 09, 2017

byncaipen

Transplants

ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP® PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes

St. Marys, West Virginia ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced the start of a Phase 1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells...Read more

Jan 24, 2017

byncaipen

Transplants

ProtoKinetix Announces Investigator Sponsored Human Clinical Trial Application Using AAGP® Has Been Approved by Health Canada

St. Marys, West Virginia ProtoKinetix, Incorporated (PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced that the Governors of the University of Alberta have received a “No Objection Letter” from Health...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.